Acadian Asset Management’s ALX Oncology ALXO Stock Holding History

Acadian Asset Management’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.71M	Buy	1,313,490 +212,465	+19%	+$380K	﹤0.01%	991
2026 Q1	$2.2M	Sell	1,101,025 -273,248	-20%	-$521K	﹤0.01%	926
2025 Q4	$1.55M	Buy	1,374,273 +153,448	+13%	+$232K	﹤0.01%	984
2025 Q3	$2.23M	Sell	1,220,825 -47,174	-4%	-$40.9K	﹤0.01%	866
2025 Q2	$525K	Sell	1,267,999 -28,332	-2%	-$14.3K	﹤0.01%	1126
2025 Q1	$806K	Buy	1,296,331 +186,883	+17%	+$224K	﹤0.01%	981
2024 Q4	$1.85M	Buy	1,109,448 +683,024	+160%	+$1.05M	0.01%	783
2024 Q3	$773K	Buy	+426,424	New	+$1.59M	﹤0.01%	981
2022 Q3	–	Sell	-20,955	Closed	-$170K	–	1662
2022 Q2	$170K	Buy	+20,955	New	+$228K	﹤0.01%	1236

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Acadian Asset Management's ALXO Position: Q2 2026 in Review

Acadian Asset Management increased its ALX Oncology (ALXO) stake by 19% in Q2 2026, buying an estimated $380K and bringing the position to 1,313,490 shares worth $2.71M. The position accounts for ﹤0.01% of the portfolio, ranked #991.

Acadian Asset Management first reported a position in ALXO in Q2 2022 and has held it in 9 quarters since. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

Acadian Asset Management held 1,313,490 shares of ALX Oncology worth $2.71M as of Q2 2026.
Acadian Asset Management bought 212,465 ALX Oncology shares in Q2 2026, an estimated $380K.
ALX Oncology made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #991 holding.
Acadian Asset Management first reported a position in ALX Oncology in Q2 2022 and has held it in 9 quarters since.
93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.